Gigli M, Rasoanaivo T W, Millot J M, Jeannesson P, Rizzo V, Jardillier J C, Arcamone F, Manfait M
Laboratory of Biomolecular Spectroscopy, Faculty of Pharmacy, Reims, France.
Cancer Res. 1989 Feb 1;49(3):560-4.
Intranuclear drug concentration in cells treated with doxorubicin (DXR) or with 4'-deoxy-4'-iododoxorubicin (IDX) was measured by means of a quantitative microspectrofluorometric technique recently developed by us. Resolution of free and bound drug contributions in fluorescence emission spectra, as collected from a microvolume of single living cell nuclei, provided concentration data with about 10% indetermination. Uptake of DXR and IDX into the nucleus of K562 cells and DXR-resistant K562/DXR cells could then be studied with a sensitive, nondestructive technique. Growth inhibitory concentrations of K562 and K562/DXR cells, when measured with respect to drug content in the medium, differed by a factor of 25 in the case of DXR and by a factor of three in the case of IDX. By contrast, intranuclear drug concentrations measured at corresponding growth inhibitory concentrations are found to be nearly constant, i.e., independent of cellular-resistant phenotype and of anthracycline structure. This result supports an identical mechanism of action for the two drugs, most probably targeted to the nucleus, and ascribes to intracellular transport the different potency of the two drugs in the two cell lines.
采用我们最近开发的定量显微分光荧光技术,测定了用阿霉素(DXR)或4'-脱氧-4'-碘阿霉素(IDX)处理的细胞中的核内药物浓度。从单个活细胞核的微体积收集的荧光发射光谱中,游离药物和结合药物贡献的分辨提供了不确定性约为10%的浓度数据。然后,可以用一种灵敏的、非破坏性技术研究DXR和IDX进入K562细胞和耐DXR的K562/DXR细胞的细胞核的情况。当根据培养基中的药物含量测量时,K562和K562/DXR细胞的生长抑制浓度,在DXR的情况下相差25倍,在IDX的情况下相差3倍。相比之下,发现在相应生长抑制浓度下测量的核内药物浓度几乎是恒定的,即与细胞抗性表型和蒽环类结构无关。这一结果支持了两种药物相同的作用机制,最有可能靶向细胞核,并将两种药物在两种细胞系中的不同效力归因于细胞内转运。